- With no positive trajectory, no incredible opportunity, and no significant growth tells the story of MannKind’s future.
- Three years of direct comparison of prescription data will be provided for my readers.
- Why changing the scoring system doesn’t change the reality of MannKind’s situation is shared with my readers.
The postmortem is in for inhaled insulin being a viable product in the market place. After Pfizer (PFE) wrote off their multi-billions in their investment for the first inhaled product, Exubera, we now have the second such product that has performed worse than the short time Exubera was available for patient’s use.
In late January 2015, MannKind’s (MNKD) inhaled product, Afrezza, was launched by Sanofi (SNY). Sanofi actively sought out physicians and their patients for 49 weeks in 2015. There results quickly validated what Pfizer had found in the marketplace, resulting in them returning Afrezza to MannKind.
Having no other options, MannKind was forced to fold-up their tent, or bluster their way through pretending they could outdo Pfizer and Sanofi, with the absurd claim they could do it with a lesser marketing plan, fewer sales representatives and less money. The latter being the classic example of not understanding the dynamics and competitiveness for participating in the drug manufacturing and marketing needed for success in the drug industry.
For the first six months of 2016, MannKind was unable to put forth any type marketing efforts, so the product lay fallow for this period. In July, MannKind, with little operating funds on hand opted for relaunching Afrezza, using an external sales force. This 40-person sales force sallied forth until November, when MannKind saw this effort wasn’t working. They canned this team and opted to undertake the third launch of Afrezza, in January 2017. This time with a sales team that was an internal group and more than doubled the number of sales representatives for the previous group.